Citigroup Maintains Buy on SpyGlass Pharma, Raises Price Target to $45

Benzinga · 22h ago
Citigroup analyst Yigal Nochomovitz maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $45.